BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...University of Pittsburgh team targeting potassium channel KCNB1...
...reticulum to nucleus signaling 1 KCNB1 - Potassium channel Kv2.1...
...A11 (MAGEA11) RAB22A member RAS oncogene family (RAB22A) Dynamin (DMN) Potassium channel Kv2.1 (KCNB1) Transient...
BioCentury | Dec 31, 2020
Distillery Therapeutics

T cell-specific targeting of KCNA3 for lupus nephritis

DISEASE CATEGORY: Autoimmune disease INDICATION: Lupus Lipid nanoparticle-based T-cell specific inhibition of the potassium channel KCNA3 could treat lupus nephritis. The nanoparticles contain an siRNA against KCNA3 and are coated with a mAb targeting CD45RO,...
BioCentury | Oct 6, 2020
Product Development

FDA pushing Makena, early drug pricing target, off the market

FDA has proposed the withdrawal of AMAG’s Makena, sending the drug, and the women who have counted on it to prevent premature births, into what could be the final turn in a roller-coaster ride that...
BioCentury | Oct 2, 2020
Regulation

Oct. 1 Quick Takes: Setback at FDA for Mesoblast; plus AMAG, Solid, COVID updates from Gilead, AZ and more

Bucking ODAC recommendation, FDA wants another trial from MesoblastMesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said FDA issued a complete response letter to a BLA for remestemcel-L to treat pediatric steroid-refractory acute GvHD. FDA’s Oncologic Drugs Advisory Committee had voted 9...
BioCentury | Aug 28, 2020
Distillery Therapeutics

Potassium channel-vesicle interaction as a target in ischemic stroke

...StrokeInterrupting the interaction between the potassium channel KCNB1...
...of KCNB1 —reduced the number of KCNB1-VAPA...
...chemical neurotoxin to mimic post-stroke conditions, the KCNB1-VAPA-targeting...
BioCentury | May 13, 2020
Emerging Company Profile

QurAlis taking three ALS programs toward clinic with $42M series A

After launching with a modest seed round in 2018, neurology company QurAlis is driving toward the clinic with a $42 million series A round to fund development of three therapies to treat amyotrophic lateral sclerosis...
BioCentury | Dec 3, 2019
Company News

Xenon licenses sodium channel inhibitors to Neurocrine to fund more advanced epilepsy programs

Xenon has exclusively licensed its sodium channel inhibitors for epilepsy to Neurocrine to focus on advancing its potassium channel modulators through the clinic. The deal adds a new indication to Neurocrine's neurology portfolio and gives...
BioCentury | Oct 30, 2019
Company News

Oct. 29 Company Quick Takes: Incyte’s JAK inhibitor beats expectations; plus Sumitomo-Intercept, Merck KGaA-Pfizer, AMAG, Regeneron-Sanofi

Incyte surges on Jakafi sales, guidance On the strength of 3Q19 sales of Jakafi ruxolitinib that beat estimates and resulted in an increase in full-year guidance, Incyte Corp. (NASDAQ:INCY) climbed $3.49 to $83.35 Tuesday, adding...
BioCentury | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...
BioCentury | Jun 4, 2019
Financial News

June 4 Financial Quick Takes: Lung Therapeutics' $36M series C; plus Strand, Hansoh, Inhibrx and more

Lung Therapeutics closes $36M series C Lung Therapeutics Inc. (Austin, Texas) raised $36 million in a series C round led by Bios Partners with participation by undisclosed new and existing investors. Lung has raised $53...
Items per page:
1 - 10 of 274